Edition:
United States

Sientra Inc (SIEN.OQ)

SIEN.OQ on NASDAQ Stock Exchange Global Select Market

10.41USD
15 Feb 2019
Change (% chg)

$-0.10 (-0.95%)
Prev Close
$10.51
Open
$10.51
Day's High
$10.51
Day's Low
$10.25
Volume
178,014
Avg. Vol
137,240
52-wk High
$26.79
52-wk Low
$8.79

Summary

Name Age Since Current Position

Jeffrey Nugent

71 2015 Chairman of the Board, Chief Executive Officer

Paul Little

2018 Chief Financial Officer, Senior Vice President, Treasurer

Charles Huiner

46 2016 Chief Operating Officer, Senior Vice President - Corporate Development and Strategy

Nicholas Simon

63 2015 Lead Independent Director

Mary Fisher

2019 Director

Keith Sullivan

60 2017 Director

Timothy Haines

59 2013 Independent Director

Kevin O'Boyle

62 2014 Independent Director

Philippe Schaison

56 2017 Independent Director

Biographies

Name Description

Jeffrey Nugent

Mr. Jeffrey M. Nugent is the Chairman of the Board, Chief Executive Officer of the Company. He was the Interim Chief Executive Officer of Biolase, Inc. from June 2014 to July 2015, in which he established a global commercialization team and chose new leaders of the sales and marketing division. Prior to that, from December 2010 to February 2013, Mr. Nugent was Founder, President and Chief Executive Officer of Precision Dermatology, Inc., a multi-channel skin care company that was acquired by Valeant Pharmaceuticals in February 2014. From 1999 to 2002, he served as the President and Chief Executive Officer of Revlon, Inc., where he led a turnaround in profitability and a global initiative of new product innovation. Prior to that, he was as Worldwide President and Chief Executive Officer of Neutrogena Corporation from 1995 to 1999 in which he led the acquisition by Johnson & Johnson and quadrupled sales to $1B within 4 years. Mr. Nugent currently serves on the Board of Neothetics, Inc. and has previously served as a director of Precision Dermatology, Inc., Myoscience, Inc. and Merz Aesthetics, Inc. Mr. Nugent began his career at Johnson & Johnson where he held increasingly senior responsibilities in Manufacturing, Finance, Research and Development, Marketing and Worldwide Vice President for Quality. Mr. Nugent holds a B.S. in mathematics from St. Joseph's College and earned his MBA in finance and marketing from Loyola University in Chicago. He served as an Artillery Officer in the United States Army.

Paul Little

Mr. Paul Little is the Chief Financial Officer, Senior Vice President, and Treasurer of the Company. Mr. Little brings 30 years of experience in finance, business strategy and operations roles, spanning life science and consumer packaged goods industries. Mr. Little recently served as Chief Operating Officer for Syneron-Candela, where he managed the aesthetic medical device Company's global supply chain and global service organization. From 2004 to 2016 Mr. Little held roles of increasing responsibility at Allergan PLC where he was a member of the senior leadership team that built Allergan into the market leader for medical aesthetics. Mr. Little held multiple roles at Allergan and was most recently Vice President, Finance and Commercial Operations for the Medical Aesthetics division. He began his career in public accounting at KPMG and holds a B.A. in Business Economics from the University of California, Santa Barbara.

Charles Huiner

Mr. Charles Huiner is the Chief Operating Officer, Senior Vice President - Corporate Development and Strategy of the Company. He previously served as Chief Strategy and Corporate Development Officer since February 2014. Prior to joining the Company, Mr. Huiner served as the Vice President of Business Development and Marketing for InTouch Health from 2007 to 2014. Before InTouch Health, Mr. Huiner held various positions in the medical aesthetics industry, including as Senior Director of Corporate Development and Strategy for Inamed Corporation from 2003 to 2006 and Vice President of Corporate Development for Isolagen, Inc. from 2006 to 2007. Mr. Huiner developed extensive transactional and strategy experience serving in corporate finance and M&A capacities at Security Capital Group (now GE Capital), Prologis Trust and NatWest Bancorp. Mr. Huiner holds a B.A. in history and American studies from Williams College and earned his MBA in marketing and finance from Northwestern University's Kellogg School.

Nicholas Simon

Mr. Nicholas J. Simon, III is the Lead Independent Director of the Company. He served as the Chairman of our Board from March 2012 until November 2015. Mr. Simon has been a Managing Director of Clarus, a venture capital firm focused on life sciences companies, since the firm's inception in 2005. Prior to Clarus, Mr. Simon was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 25 years of operating and investment experience in the biopharmaceutical industry including Genentech from 1989 to 2000 where he was Vice President of Business and Corporate Development. Mr. Simon is currently a member of the board of directors of Gritstone Oncology, Lycera, and Nuvelution Pharma. He has also been a member of the board of directors of numerous private and public life sciences companies including Achillion, Avanir Pharmaceuticals (acquired by Otsuka Pharmaceuticals), Barrier Therapeutics (acquired by Stiefel Laboratories), BioVitrum AB (acquired by AstraZeneca), QuatRX Pharmaceuticals, Rigel, Sangstat (acquired by Genzyme). Mr. Simon is also a member of the foundation board at the J. David Gladstone Institutes, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a B.S. in microbiology from the University of Maryland and an MBA from Loyola University.

Mary Fisher

Keith Sullivan

Mr. Keith J. Sullivan is the Director of the Company. Mr. Sullivan most recently was Chief Commercial Officer and President, North America of ZELTIQ Aesthetics, Inc., a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform under the Coolsculpting® brand. Mr. Sullivan led the restructuring of the global commercial organization resulting in a nearly 50% 4-year CAGR leading to an acquisition this year by Allergan. Mr. Sullivan, who has more than 30 years of senior sales leadership experience in the medical device industry, has previously held leadership positions with Medicis Pharmaceuticals, Reliant Technologies, Medtronic, Vision Quest Laser and Coherent Medical. Mr. Sullivan received a Bachelor of Business Administration from the College of William and Mary.

Timothy Haines

Mr. Timothy Haines is an Independent Director of the Company. He joined Abingworth, a life science and healthcare private investment firm, in 2005 and is currently a partner. From 2000 to 2005, he was Chief Executive of Astex Therapeutics, an Abingworth portfolio company. From 1993 to 2000, Mr. Haines was Chief Executive Officer of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the SU and Europe, including CEO of Thackray Inc. and General Manager of Baxter UK. Current and past board positions include Astex Pharmaceuticals, Chroma, Fovea, Pixium Vision, PowerMed, Kspine, Stanmore Implants, Lombard Medical, Proteon and MEDIAN Technologies. Mr. Haines received a B.Sc. from Exeter University and an MBA from INSEAD.

Kevin O'Boyle

Mr. Kevin C. O'Boyle, CPA is an Independent Director of the Company. From December 2010 to July 2011, Mr. O'Boyle served as Senior Vice President and Chief Financial Officer at Advanced BioHealing, Inc. until it was acquired by Shire Plc. From early 2003 to September 2009, Mr. O'Boyle served as Chief Financial Officer of NuVasive, Inc. Mr. O'Boyle currently serves as a director of GenMark Diagnostics, Inc., Durata Therapeutics, Inc., Tornier N.V. and Zeltiq Aesthetics, Inc. Mr. O'Boyle received a B.S. in accounting from Rochester Institute of Technology and completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School.

Philippe Schaison

Mr. Philippe A. Schaison is an Independent Director of the Company. He has extensive experience leading global aesthetic organizations. In November 2016, Mr. Schaison joined Syneron Medical Ltd., a leading global aesthetic device company, and currently serves as CEO of Syneron Candela North America and Global Executive Vice President Strategy and Business Development. Previously, Mr. Schaison served as President of Allergan’s U.S. aesthetic and dermatology business from September 2013 until October 2016. In that position, he led the Facial Aesthetic, Plastic and MedDerm/Skin Medical business unit, an organization of over 2,000 professionals focused on the company’s Botox® and fillers franchises. Prior to joining Allergan, Mr. Schaison served as President, World Wide Travel Retail & Regional President, LATAM and MEA, at Clarins in New York from 2010 to August 2013. Earlier, Mr. Schaison served as CEO for Aesthetic Factors, a manufacturer of point-of-care systems for regenerative medicines and as Vice President of Global Skin Care for Johnson & Johnson, with P&L responsibility for Aveeno, Clean & Clear, Lubriderm, and Ambi, and in executive positions at L'Oréal. Mr. Schaison sits on the Board of the Galien Foundation and SENTÉ, Inc., a privately held specialty aesthetics company. He earned his MBA (Marketing) from the Hautes Etudes Commerciales (H.E.C.) in Paris, and a Doctorate in Pharmacy (Industrial) from the University of Paris.

Basic Compensation

Name Fiscal Year Total

Jeffrey Nugent

2,475,500

Paul Little

--

Charles Huiner

956,682

Nicholas Simon

167,509

Mary Fisher

--

Keith Sullivan

781,699

Timothy Haines

170,009

Kevin O'Boyle

185,009

Philippe Schaison

337,252
As Of  30 Dec 2017